TBA-354 is primarily investigated for its potential therapeutic applications in the treatment of bacterial infections, particularly those caused by drug-resistant strains. It belongs to a class of compounds designed to target and inhibit bacterial enzymes essential for their survival, making it a promising candidate for addressing the growing issue of antibiotic resistance. Research focuses on its efficacy against specific pathogens, such as Mycobacterium tuberculosis, which causes tuberculosis. Its development is part of ongoing efforts to create new antibiotics that can overcome resistance mechanisms and provide effective treatment options for challenging infections.